Milliman：2025年美国器官与组织移植研究报告：预估成本、利用率、新兴问题及解决方案（英文版）（19页）.pdf

1、MILLIMAN REPORT 2025 U.S.organ and tissue transplants:Estimated costs and utilization,emerging issues,and solutions February 2025 Nick Ortner,FSA,MAAA,Senior Consulting Actuary Hanna Holzer,Senior Actuarial Manager MILLIMAN REPORT Table of contents 1.OVERVIEW.1 2.COSTS PMPM,BILLED CHARGES,AND UTILIZ

2、ATION.3 COMPONENTS OF BILLED CHARGES.3 BASIS OF UTILIZATION AND BILLED CHARGES.6 HOSPITAL LENGTHS OF STAY.6 ANNUAL NUMBER OF TRANSPLANTS.7 3.EMERGING ISSUES AND POTENTIAL SOLUTIONS.8 BENCHMARKING AND CONTEMPORARY MARKET INTELLIGENCE.8 ORGAN TRANSPLANT DISTRIBUTION AND INEQUALITIES.8 ORGAN AVAILABILI

3、TY.10 ORGAN VIABILITY.11 BONE MARROW TRANSPLANT DEVELOPMENTS.12 SECURING THE U.S.ORGAN PROCUREMENT AND TRANSPLANTATION NETWORK ACT.12 4.OTHER DATA AND POTENTIAL ANALYSIS OPPORTUNITIES.13 ACTUAL MARKET PRICES WILL VARY FROM MILLIMAN BILLED CHARGES.13 ACTUAL COSTS COMPARED TO MILLIMAN COSTS.13 BILLED

4、CHARGE COMPONENT DETAILS.14 OTHER POTENTIAL DATA ANALYSES.14 BACKGROUND ON DATA SETS.15 5.FIGURE INDEX.16 ACKNOWLEDGMENTS.17 MILLIMAN REPORT 2025 U.S.organ and tissue transplants:1 Estimated costs and utilization,emerging issues,and solutions February 2025 1.Overview This 2025 report represents Mill

5、imans periodic summary of estimated U.S.average utilization,billed charges,and resulting costs per member per month(PMPM)for organ and tissue transplants.Since the last report(released in February 2020),we expanded the underlying data used to produce the cost estimates.Any comparisons to the 2020 re

6、port should note that the 2020 projections(released in February 2020)were developed without considering the impact of COVID-19 on transplants.The short-and long-term effects of COVID-19 on transplant use,costs,demand,and other aspects are outside the scope of this report.The report covers estimates